Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

touchCONGRESS for touchONCOLOGY

Listen to Prof. Gianantonio Rosti, an expert in CML, as he reviews key data presented at the 2024 EHA Hybrid congress and the ESH-iCMLf 26th Annual John Goldman Conference, on tyrosine kinase inhibitors (TKIs) for treating chronic myeloid leukaemia (CML) in the first-and later-line settings. Prof. Rosti is then joined by fellow experts, Prof. Susanne Saussele and Dr Carla Boquimpani, to consider the implications of these data for current and future clinical practice.

Overview

• Data reviews with Prof. Rosti
• Expert panel discussions with Prof. Susanne Saussele and Dr Carla Boquimpani on the themes below

Clinical themes

1. Approved and emerging TKIs for CML in the first-line setting
2. Approved and emerging TKIs for CML in the second- and later-line settings
3. Potential impact of emerging data on current and future clinical practice

The internationally renowned multiple myeloma expert faculty

• Prof. Gianantonio Rosti: Meldola, Italy
• Prof. Susanne Saussele: Mannheim, Germany
• Dr Carla Boquimpani: Rio de Janeiro, Brazil

This touchPODCAST is for HCPs globally with the exclusion of the USA, the UK and Japan.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME. 

For further information visit our website: TBC